IL327180A - קולטנים כימריים ממוקדי cd19/cd20 דו-ספציפיים ושימושיהם - Google Patents
קולטנים כימריים ממוקדי cd19/cd20 דו-ספציפיים ושימושיהםInfo
- Publication number
- IL327180A IL327180A IL327180A IL32718026A IL327180A IL 327180 A IL327180 A IL 327180A IL 327180 A IL327180 A IL 327180A IL 32718026 A IL32718026 A IL 32718026A IL 327180 A IL327180 A IL 327180A
- Authority
- IL
- Israel
- Prior art keywords
- cell
- car
- cells
- seq
- amino acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4221—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
- A61K2239/29—Multispecific CARs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363587646P | 2023-10-03 | 2023-10-03 | |
| PCT/US2024/049668 WO2025076144A1 (en) | 2023-10-03 | 2024-10-02 | Bispecific cd19/cd20-targeted chimeric antigen receptors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL327180A true IL327180A (he) | 2026-05-01 |
Family
ID=95283862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL327180A IL327180A (he) | 2023-10-03 | 2024-10-02 | קולטנים כימריים ממוקדי cd19/cd20 דו-ספציפיים ושימושיהם |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP4788705A1 (he) |
| KR (1) | KR20260082322A (he) |
| CN (1) | CN122122190A (he) |
| AU (1) | AU2024355525A1 (he) |
| IL (1) | IL327180A (he) |
| WO (1) | WO2025076144A1 (he) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026107075A1 (en) * | 2024-11-13 | 2026-05-21 | Genentech, Inc. | Methods of treating multiple sclerosis with cd19-cd20 dual car-t cells |
| WO2026107085A1 (en) * | 2024-11-13 | 2026-05-21 | Genentech, Inc. | Methods of treating lupus with cd19-cd20 dual car-t cells |
| CN120795167B (zh) * | 2025-04-15 | 2026-05-08 | 佰芮慷(广州)细胞医药科技有限公司 | 一种靶向人eb病毒的嵌合抗原受体car、car-nk细胞及用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016100232A1 (en) * | 2014-12-15 | 2016-06-23 | The Regents Of The University Of California | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 |
| KR102357312B1 (ko) * | 2015-03-04 | 2022-02-03 | 아이쥐엠 바이오사이언스 인코포레이티드 | Cd20 결합 분자 및 그의 용도 |
| US11535662B2 (en) * | 2017-01-26 | 2022-12-27 | Novartis Ag | CD28 compositions and methods for chimeric antigen receptor therapy |
| IL326873A (he) * | 2017-12-29 | 2026-04-01 | Memorial Sloan Kettering Cancer Center | קולטני אנטיגנים כימריים מוגברים ושימושיהם |
| MX2021002702A (es) * | 2018-09-10 | 2021-05-12 | Atara Biotherapeutics Inc | Metodos para expandir celulas t del receptor de antigeno quimerico especificas de antigenos, composiciones y usos relacionados con las mismas. |
| WO2024086842A2 (en) * | 2022-10-21 | 2024-04-25 | Memorial Sloan-Kettering Cancer Center | Cells and compositions for treating cancer |
-
2024
- 2024-10-02 IL IL327180A patent/IL327180A/he unknown
- 2024-10-02 WO PCT/US2024/049668 patent/WO2025076144A1/en not_active Ceased
- 2024-10-02 CN CN202480070301.3A patent/CN122122190A/zh active Pending
- 2024-10-02 AU AU2024355525A patent/AU2024355525A1/en active Pending
- 2024-10-02 EP EP24875338.6A patent/EP4788705A1/en active Pending
- 2024-10-02 KR KR1020267013467A patent/KR20260082322A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4788705A1 (en) | 2026-08-12 |
| AU2024355525A1 (en) | 2026-04-02 |
| KR20260082322A (ko) | 2026-06-04 |
| WO2025076144A1 (en) | 2025-04-10 |
| CN122122190A (zh) | 2026-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202108759SA (en) | Humanized anti-dll3 chimeric antigen receptors and uses thereof | |
| SG11202100252SA (en) | BISPECIFIC ANTI-BCMA x ANTI-CD3 ANTIBODIES AND USES THEREOF | |
| HUE073404T2 (hu) | CD19-et és CD20-at célzó kombinált kiméra antigén receptorok és azok alkalmazásai | |
| GB2606869B (en) | CLL1-Targeting chimeric antigen receptor and application thereof | |
| SG11202100205UA (en) | Ror-1 specific chimeric antigen receptors and uses thereof | |
| IL274147A (he) | נוגדנים וקולטני אנטיגן כימריים מוכווניי אנטיגן הבשלה של תאי b | |
| IL283493A (he) | נוגדנים דו-ספציפיים נגד-muc16 ונגד-cd28 ושימושים שלהם | |
| IL287487A (he) | קולטני אנטיגן כימיים עמידים לריטוקסימאב ושימושיהם | |
| IL304554A (he) | קולטני אנטיגן כימריים ביספציפיים הנקשרים ל- cd19 ו- cd22 | |
| SG11202109052YA (en) | Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof | |
| IL287156A (he) | קולטני אנטיגן כימריים לקולטן 1 אנטי-פולאט אנושיים ושימושים בהם | |
| IL312003A (he) | קולטני anti-steap2 כימריים ושימושיהם | |
| SG11202012155RA (en) | Cd79a chimeric antigen receptors | |
| IL281129A (he) | שיטות והרכבים המכילים רצפטורים של אנטיגן כימרי b7h3 | |
| IL318416A (he) | קולטי אנטיגנים כימריים ספציפיים ל-gprc5d ול-bcma | |
| EP3240805A4 (en) | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 | |
| EP4174093A4 (en) | FULLY HUMANIZED BISPECIFIC CHIMERIC ANTIGEN RECEPTOR FOR TARGETING CD19 AND CD22 AND USE THEREOF | |
| IL308361A (he) | נוגדנים בעלי ספציפיות כפולה ושימושיהם | |
| IL321365A (he) | קולטן אנטיגן כימרי | |
| IL279115A (he) | מינון של נוגדן בי-ספציפי שקושר cd123 ו- cd3 | |
| EP4323387A4 (en) | ENHANCED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES | |
| CA3306870A1 (en) | Bispecific cd19/cd20-targeted chimeric antigen receptors and uses thereof | |
| EP4041404A4 (en) | HUMANIZED ANTI-ALPHA RECEPTOR 4 ANTIBODY (GRF-ALPHA-4) AND CHIMERIC ANTIGEN RECEPTOR (CAR) | |
| CA3287693A1 (en) | Bispecific chimeric antigen receptors targeting bcma and cd19 | |
| CA3270475A1 (en) | Humanized anti-hla-g chimeric antigen receptors and uses thereof |